Titanovo Logo
Back to Cell Types

SK-OV-3Homo sapiens (Human)Cancer cell line

Also known as: SKOV-3, SK-OV3, SK.OV.3, SKOV3, Skov3, SKO3, SKOV3 (S), SKVO3 (Occasionally.), SCOV3 (Occasionally.), SCOV-3 (Occasionally.)

🤖 AI SummaryBased on 15 publications

Quick Overview

Human ovarian cancer cell line used in cancer research and drug development.

Detailed Summary

SK-OV-3 is a human ovarian cancer cell line derived from a serous carcinoma. It is widely used in research for studying ovarian cancer biology, drug screening, and therapeutic development. The cell line has been characterized in multiple studies for its genetic and molecular profiles, including mutations in TP53 and other key oncogenes. It is utilized in various experimental models, such as xenografts in immunocompromised mice, to evaluate tumor growth and response to treatments. Research on SK-OV-3 has contributed to understanding the mechanisms of chemotherapy resistance and the role of specific genetic alterations in cancer progression.

Research Applications

Cancer biology researchDrug screening and developmentTherapeutic target identificationXenograft models for tumor growth studiesChemotherapy resistance mechanisms

Key Characteristics

TP53 mutationSerous carcinoma originUsed in in vivo and in vitro studiesExpression of specific oncogenes and tumor markers
Generated on 6/15/2025

Basic Information

Database IDCVCL_0532
SpeciesHomo sapiens (Human)
Tissue SourceAscites[UBERON:UBERON_0007795]

Donor Information

Age64
Age CategoryAdult
SexFemale
Racecaucasian

Disease Information

DiseaseOvarian serous cystadenocarcinoma
LineageOvary/Fallopian Tube
SubtypeSerous Ovarian Cancer
OncoTree CodeSOC

DepMap Information

Source TypeATCC
Source IDACH-000811_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleAPCp.Thr1556Leufs*9 (c.4666delA)Heterozygous-from parent cell line SK-OV-3
MutationSimpleFBXW7p.Arg505Leu (c.1514G>T)Heterozygous-from parent cell line SK-OV-3
MutationSimplePIK3CAp.His1047Arg (c.3140A>G)Unspecified-PubMed=25926053, PubMed=20570890
MutationSimpleTP53p.Ser90Profs*33 (c.267delC)Homozygous-from parent cell line SK-OV-3

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
11
D10S1248
13,16,17
D12S391
21,22
D13S317
8,11
D16S539
12
D18S51
16,17
D19S433
14,14.2
D1S1656
11,17.3
D21S11
30,31,31.2
D22S1045
11,16
D2S1338
18,23
D2S441
10,11.3
D3S1358
13,14
D5S818
11
D7S820
13,14
D8S1179
14,15
FGA
23,24,25
Penta D
12,13
Penta E
5,13
TH01
9,9.3
TPOX
8,11
vWA
17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Radiosensitivity profiles from a panel of ovarian cancer cell lines exhibiting genetic alterations in p53 and disparate DNA-dependent protein kinase activities.

Long S.B.T., Vonguyen L., Chen D.J., Gray J.W., Chen F.-Q.

Oncol. Rep. 23:1021-1026(2010).

DOIPubMedPMC

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

DOIPubMedPMC

CPEB4-promoted paclitaxel resistance in ovarian cancer in vitro relies on translational regulation of CSAG2.

Zhang Y.-Q., Gan H.-Y., Zhao F., Ma X.-M., Xie X.-F., Huang R., Zhao J.

Front. Pharmacol. 11:600994.1-600994.10(2020).

DOIPubMedPMC

Identification of ovarian high-grade serous carcinoma cell lines that show estrogen-sensitive growth as xenografts in immunocompromised mice.

Herodek B., Arteagabeitia A.B., Valenti M., Kirkin V.

Sci. Rep. 10:10799-10799(2020).

DOIPubMedPMC

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOIPubMedPMC

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOIPubMedPMC

Integrated genomic, epigenomic, and expression analyses of ovarian cancer cell lines.

Velculescu V.E., Scharpf R.B.

Cell Rep. 25:2617-2633(2018).

DOIPubMedPMC

Interrogation of functional cell-surface markers identifies CD151 dependency in high-grade serous ovarian cancer.

Drapkin R.I., Ailles L., Mes-Masson A.-M., Rottapel R.

Cell Rep. 18:2343-2358(2017).

DOIPubMed

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

DOIPubMedPMC

A map of mobile DNA insertions in the NCI-60 human cancer cell panel.

Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.

Mob. DNA 7:20.1-20.11(2016).

DOIPubMedPMC

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOIPubMedPMC

Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.

Vandesompele J.

Sci. Data 3:160052-160052(2016).

DOIPubMedPMC

Characterization of ovarian cancer cell lines as in vivo models for preclinical studies.

Noonan A.M., Annunziata C.M.

Gynecol. Oncol. 142:332-340(2016).

DOIPubMedPMC

The effectiveness of chemotherapy and electrochemotherapy on ovarian cell lines in vitro.

Deszcz I., Zalewski J., Kulbacka J.

Neoplasma 63:450-455(2016).

DOIPubMed

Isolation and characterization of side population cells from the human ovarian cancer cell line SK-OV-3.

Ruan Z.-Y., Liu J.-H., Kuang Y.-P.

Exp. Ther. Med. 10:2071-2078(2015).

DOIPubMedPMC

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

DOIPubMedPMC

Metabolic signatures differentiate ovarian from colon cancer cell lines.

Suhre K., Rafii A.

J. Transl. Med. 13:223.1-223.12(2015).

DOIPubMedPMC

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Golub T.R., Root D.E., Hahn W.C.

Sci. Data 1:140035-140035(2014).

DOIPubMedPMC

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

DOIPubMed

Profiling of actionable gene alterations in ovarian cancer by targeted deep sequencing.

Ichikawa H., Shibata T., Yokota J., Okamoto A., Kohno T.

Int. J. Oncol. 46:2389-2398(2015).

DOIPubMed

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

DOIPubMed

Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.

Helleman J.

PLoS ONE 9:E103988-E103988(2014).

DOIPubMedPMC

High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.

Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.

PLoS ONE 9:E92047-E92047(2014).

DOIPubMedPMC

In-depth proteomic analyses of ovarian cancer cell line exosomes reveals differential enrichment of functional categories compared to the NCI 60 proteome.

Kislinger T.

Biochem. Biophys. Res. Commun. 445:694-701(2014).

DOIPubMed

The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.

Hirshfield K.M., Oltvai Z.N., Vazquez A.

Cancer Metab. 1:20.1-20.13(2013).

DOIPubMedPMC

Type-specific cell line models for type-specific ovarian cancer research.

Shumansky K., Shah S.P., Kalloger S.E., Huntsman D.G.

PLoS ONE 8:E72162-E72162(2013).

DOIPubMedPMC

Global proteome analysis of the NCI-60 cell line panel.";

Wilhelm M., Kuster B.

Cell Rep. 4:609-620(2013).

DOIPubMed

The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.

Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.

Cancer Res. 73:4372-4382(2013).

DOIPubMedPMC

Evaluating cell lines as tumour models by comparison of genomic profiles.

Domcke S., Sinha R., Levine D.A., Sander C., Schultz N.

Nat. Commun. 4:2126.1-2126.10(2013).

DOIPubMedPMC

BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.

Mills G.B., Hennessy B.T.

Mol. Oncol. 7:567-579(2013).

DOIPubMedPMC

DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.

Lessey B.A., Jordan V.C., Bradford A.P.

Gynecol. Oncol. 127:241-248(2012).

DOIPubMedPMC

Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.

Miyazaki K.

Hum. Pathol. 43:2197-2206(2012).

DOIPubMed

Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.

Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.

Science 336:1040-1044(2012).

DOIPubMedPMC

Essential gene profiles in breast, pancreatic, and ovarian cancer cells.

Rottapel R., Neel B.G., Moffat J.

Cancer Discov. 2:172-189(2012).

DOIPubMedPMC

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOIPubMedPMC

Identification of cancer cell-line origins using fluorescence image-based phenomic screening.

Yoon C.N., Chang Y.-T.

PLoS ONE 7:E32096-E32096(2012).

DOIPubMedPMC

Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location.

Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.

PLoS ONE 7:E31628-E31628(2012).

DOIPubMedPMC

JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.

Kong D.-X., Yamori T.

Bioorg. Med. Chem. 20:1947-1951(2012).

DOIPubMed

Genomic complexity and AKT dependence in serous ovarian cancer.";

Taylor B.S., Sander C., Rosen N., Levine D.A., Solit D.B.

Cancer Discov. 2:56-67(2012).

DOIPubMedPMC

Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.

Ambudkar S.V., Gottesman M.M.

Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011).

DOIPubMedPMC

Therapeutic reactivation of mutant p53 protein by quinazoline derivatives.

Ding A., Baguley B.C.

Invest. New Drugs 30:2035-2045(2012).

DOIPubMed

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

DOIPubMedPMC

One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.

Fogh J., Fogh J.M., Orfeo T.

J. Natl. Cancer Inst. 59:221-226(1977).

DOIPubMed

Absence of HeLa cell contamination in 169 cell lines derived from human tumors.

Fogh J., Wright W.C., Loveless J.D.

J. Natl. Cancer Inst. 58:209-214(1977).

DOIPubMed

Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines.

Mistry P., Kelland L.R., Loh S.Y., Abel G., Murrer B.A., Harrap K.R.

Cancer Res. 52:6188-6193(1992).

PubMed

The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines.

Mistry P., Kelland L.R., Abel G., Sidhar S., Harrap K.R.

Br. J. Cancer 64:215-220(1991).

DOIPubMedPMC

Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.

Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.

J. Natl. Cancer Inst. 83:757-766(1991).

DOIPubMed

Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes.

Harrap K.R.

Br. J. Cancer 59:527-534(1989).

DOIPubMedPMC

Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.

Cancer Res. 48:589-601(1988).

PubMed

Human tumor lines for cancer research.";

Fogh J.

Cancer Invest. 4:157-184(1986).

DOIPubMed

Establishment and characterisation of three new human ovarian carcinoma cell lines and initial evaluation of their potential in experimental chemotherapy studies.

Shellard S.A., Rupniak H.T.

Int. J. Cancer 39:219-225(1987).

DOIPubMed

Comparative properties of five human ovarian adenocarcinoma cell lines.

Buick R.N., Pullano R., Trent J.M.

Cancer Res. 45:3668-3676(1985).

PubMed

Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.

Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.

Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).

DOIPubMedPMC

Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.

Rousset M., Zweibaum A., Fogh J.

Cancer Res. 41:1165-1170(1981).

PubMed

Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer.

van Zijl P.L.

Eur. J. Cancer 31A:230-237(1995).

DOIPubMed

p53 gene mutation analysis and antisense-mediated growth inhibition of human ovarian carcinoma cell lines.

Skilling J.S., Squatrito R.C., Connor J.P., Niemann T., Buller R.E.

Gynecol. Oncol. 60:72-80(1996).

DOIPubMed

Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines.

Johnson S.W., Laub P.B., Beesley J.S., Ozols R.F., Hamilton T.C.

Cancer Res. 57:850-856(1997).

PubMed

Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide.

Sabichi A.L., Hendricks D.T., Bober M.A., Birrer M.J.

J. Natl. Cancer Inst. 90:597-605(1998).

DOIPubMed

Mutation of the PTEN tumor suppressor gene is not a feature of ovarian cancers.

Berchuck A., Futreal P.A.

Gynecol. Oncol. 70:13-16(1998).

DOIPubMed

Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells.

Lau K.-M., Mok S.C., Ho S.-M.

Proc. Natl. Acad. Sci. U.S.A. 96:5722-5727(1999).

DOIPubMedPMC

Systematic variation in gene expression patterns in human cancer cell lines.

Botstein D., Brown P.O.

Nat. Genet. 24:227-235(2000).

DOIPubMed

Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines.

Rauh-Adelmann C., Lau K.-M., Sabeti N., Long J.P., Mok S.C., Ho S.-M.

Mol. Carcinog. 28:236-246(2000).

DOIPubMed

Short tandem repeat profiling provides an international reference standard for human cell lines.

Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.

Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).

DOIPubMedPMC

Archipelago regulates cyclin E levels in Drosophila and is mutated in human cancer cell lines.

Moberg K.H., Bell D.W., Pronk-Wahrer D.C.R., Haber D.A., Hariharan I.K.

Nature 413:311-316(2001).

DOIPubMed

A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer.

Dodson A.R., Navabi H., Miller K.D., Balaton A.J.

Am. J. Clin. Pathol. 117:81-89(2002).

DOIPubMed

Multicolor spectral karyotyping of serous ovarian adenocarcinoma.";

Rao P.H., Harris C.P., Lu X.-Y., Li X.-N., Mok S.C., Lau C.C.

Genes Chromosomes Cancer 33:123-132(2002).

DOIPubMed

CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential.

Auersperg N., Birrer M.J.

Oncogene 21:4435-4447(2002).

DOIPubMed

Differentially regulated genes as putative targets of amplifications at 20q in ovarian cancers.

Takayama M., Sato A., Inazawa J.

Jpn. J. Cancer Res. 93:1114-1122(2002).

DOIPubMedPMC

Gene expression patterns in ovarian carcinomas.";

Sikic B.I.

Mol. Biol. Cell 14:4376-4386(2003).

DOIPubMedPMC

HLA class I and II genotype of the NCI-60 cell lines.";

Morse H.C. 3rd, Stroncek D., Marincola F.M.

J. Transl. Med. 3:11.1-11.8(2005).

DOIPubMedPMC

Selenium binding protein 1 in ovarian cancer.";

Bandera C.A., Welch W.R., Berkowitz R.S., Mok S.C., Ng S.-W.

Int. J. Cancer 118:2433-2440(2006).

DOIPubMed

Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.

Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.

Mol. Cancer Ther. 5:2606-2612(2006).

DOIPubMedPMC

Genetic changes in the evolution of multidrug resistance for cultured human ovarian cancer cells.

Lam W.L., Ling V.

Genes Chromosomes Cancer 46:1069-1079(2007).

DOIPubMed

DNA fingerprinting of the NCI-60 cell line panel.";

Chanock S.J., Weinstein J.N.

Mol. Cancer Ther. 8:713-724(2009).

DOIPubMedPMC

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

DOIPubMedPMC

Web Resources

en.wikipedia.orgdtp.cancer.govsynapse.orgstrap.nci.nih.govdpsc.ccbr.utoronto.cathermofisher.commskcc.orgtcpaportal.org